Laura Shawver Biography and Net Worth

Director of ARS Pharmaceuticals

Laura Shawver, Ph.D., has served as a member of our Board of Directors since the closing of the merger in November 2022 and as a member of the Silverback Therapeutic, Inc.’s board of directors from April 2020 to November 2022. Dr. Shawver also previously served as Silverback Therapeutic Inc.’s Chief Executive Officer from April 2020 through August 2022. Dr. Shawver has served as the President and Chief Executive Officer of Capstan Therapeutics, Inc., a biotechnology company focused on in vivo engineering of cells through targeted lipid nanoparticles, since September 2022. Dr. Shawver has also served as a member of the board of directors for Relay Therapeutics, Inc. (Nasdaq: RLAY) since 2017. Previously, Dr. Shawver served as the President and Chief Executive Officer and as a member of the board of directors of Synthorx, Inc. (formerly Nasdaq: THOR) from 2017 until its acquisition by Sanofi S.A. in January 2020. From 2011 to 2018, she served as Chief Executive Officer and Director of Cleave Biosciences, a biopharmaceutical company. Previously, Dr. Shawver was an Entrepreneur in Residence for 5AM Ventures and Chief Executive Officer of Phenomix Corp., and held various positions at SUGEN, Inc. and Berlex Biosciences (formerly Triton Biosciences). Dr. Shawver holds a B.S in microbiology and a Ph.D. in pharmacology, both from the University of Iowa.

What is Laura Shawver's net worth?: The estimated net worth of Laura Shawver is at least $2.10 million as of April 7th, 2025. Dr. Shawver owns 210,346 shares of ARS Pharmaceuticals stock worth more than $2,097,150 as of December 4th. This net worth estimate does not reflect any other investments that Dr. Shawver may own. Learn More about Laura Shawver's net worth.
How do I contact Laura Shawver?: The corporate mailing address for Dr. Shawver and other ARS Pharmaceuticals executives is 500 Fairview Ave N Suite 600, Seattle WA, 98109. ARS Pharmaceuticals can also be reached via phone at 206-456-2900 and via email at [email protected]. Learn More on Laura Shawver's contact information.
Has Laura Shawver been buying or selling shares of ARS Pharmaceuticals?: Laura Shawver has not been actively trading shares of ARS Pharmaceuticals during the last ninety days. Most recently, Laura Shawver sold 50,002 shares of the business's stock in a transaction on Monday, April 7th. The shares were sold at an average price of $12.30, for a transaction totalling $615,024.60. Following the completion of the sale, the director now directly owns 210,346 shares of the company's stock, valued at $2,587,255.80. Learn More on Laura Shawver's trading history.
Who are ARS Pharmaceuticals' active insiders?: ARS Pharmaceuticals' insider roster includes Justin Chakma (Chief Business Officer), Brian Dorsey (Chief Operating Officer), Alexander Fitzpatrick (Chief Legal Officer), Eric Karas (Chief Commercial Officer), Richard Lowenthal (President and Chief Executive Officer), Brent Saunders (Director), Kathleen Scott (Chief Financial Officer), Laura Shawver (Director), Sarina Tanimoto (Chief Medical Officer), and Peter Thompson (Director). Learn More on ARS Pharmaceuticals' active insiders.
Are insiders buying or selling shares of ARS Pharmaceuticals?: In the last twelve months, insiders at the sold shares 23 times. They sold a total of 1,870,472 shares worth more than $27,822,091.20. The most recent insider tranaction occured on November, 13th when COO Brian Dorsey sold 21,828 shares worth more than $190,121.88. Insiders at ARS Pharmaceuticals own 33.5% of the company. Learn More about insider trades at ARS Pharmaceuticals.
Information on this page was last updated on 11/13/2025.

Laura Shawver Insider Trading History at ARS Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/7/2025	Sell	50,002	$12.30	$615,024.60	210,346
3/6/2025	Sell	49,600	$11.21	$556,016.00	210,346
2/3/2025	Sell	50,000	$12.31	$615,500.00	210,346
1/6/2025	Sell	50,000	$11.10	$555,000.00	210,346
12/4/2024	Sell	14,772	$13.75	$203,115.00	210,346
12/2/2024	Sell	97,244	$13.56	$1,318,628.64	210,346
9/1/2023	Sell	100,000	$7.71	$771,000.00	210,346
8/4/2023	Sell	18,897	$7.06	$133,412.82	210,346
8/2/2023	Sell	36,281	$7.09	$257,232.29	210,346
7/6/2023	Sell	33,510	$6.34	$212,453.40	210,346
7/3/2023	Sell	26,520	$6.72	$178,214.40	210,346
6/1/2023	Sell	73,059	$6.80	$496,801.20	210,346
5/9/2023	Sell	42,900	$5.31	$227,799.00	210,346

Laura Shawver Buying and Selling Activity at ARS Pharmaceuticals

ARS Pharmaceuticals Company Overview

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Today's Range

Now: $9.97

$9.44

$10.02

50 Day Range

MA: $9.36

$6.73

$11.58

2 Week Range

Now: $9.97

$6.66

$18.90

Volume

1,431,706 shs

Average Volume

2,390,232 shs

Market Capitalization

$985.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82